Jill Walker

PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project

Fred R. Hirsch, Abigail McElhinny, Dave Stanforth et al. · Journal of Thoracic Oncology · 2016 · 1.3K citations · Full text

Medicine, Cancer Biology, Oncology +14

Gefitinib Treatment in EGFR Mutated Caucasian NSCLC: Circulating-Free Tumor DNA as a Surrogate for Determination of EGFR Status

Jean‐Yves Douillard, Gyula Ostoros, Manuel Cobo et al. · Journal of Thoracic Oncology · 2014 · 445 citations · Full text

Medicine, Molecular Medicine, Oncology +17

Agreement between Programmed Cell Death Ligand-1 Diagnostic Assays across Multiple Protein Expression Cutoffs in Non–Small Cell Lung Cancer

M. Ratcliffe, Alan Sharpe, Anita Midha et al. · Clinical Cancer Research · 2017 · 304 citations

Medicine, Oncology, Cancer Immunology +16

Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma

Marlon C. Rebelatto, Anita Midha, Amita Mistry et al. · Diagnostic Pathology · 2016 · 179 citations · Full text

Medicine, Oncology, Cancer Immunology +16

Antitumor Effects and Biomarkers of Activity of AZD0530, a Src Inhibitor, in Pancreatic Cancer

N.V. Rajeshkumar, Aik Choon Tan, Elizabeth De Oliveira et al. · Clinical Cancer Research · 2009 · 89 citations

Medicine, Oncology, Pharmacology +17